Electromed Inc (ELMD)vsNovartis AG ADR (NVS)
ELMD
Electromed Inc
$25.10
-2.49%
HEALTHCARE · Cap: $215.16M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 82063% more annual revenue ($56.58B vs $68.86M). NVS leads profitability with a 23.9% profit margin vs 13.1%. ELMD appears more attractively valued with a PEG of 0.35. ELMD earns a higher WallStSmart Score of 68/100 (B-).
ELMD
Strong Buy68
out of 100
Grade: B-
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.6%
Fair Value
$19.96
Current Price
$25.10
$5.14 premium
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 20 in profit
16.3% revenue growth
Earnings expanding 45.5% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Moderate valuation
Smaller company, higher risk/reward
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ELMD
The strongest argument for ELMD centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 16.3% demonstrates continued momentum. PEG of 0.35 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : ELMD
The primary concerns for ELMD are P/E Ratio, Market Cap.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
ELMD profiles as a growth stock while NVS is a declining play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
ELMD is growing revenue faster at 16.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ELMD scores higher overall (68/100 vs 51/100) and 16.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Electromed Inc
HEALTHCARE · MEDICAL DEVICES · USA
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation (HFCWO) therapy in lung care for patients of all ages in the United States. and internationally. The company is headquartered in New Prague, Minnesota.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?